Have a personal or library account? Click to login
An Update on Tardive Dyskinesia: From Phenomenology to Treatment Cover

An Update on Tardive Dyskinesia: From Phenomenology to Treatment

Tremor and Other Hyperkinetic Movements
Volume 3 (2013): Issue 0
By: Olga Waln and  Joseph Jankovic  
Open Access
|Jul 2013

References

  1. 1
    SchoneckerMParoxysmal dyskinesia as the effect of megaphenNervenarzt19572855055313517450
    Back to article
  2. 2
    FaurbyeARaschPJPetersenPBBrandborgGPakkenbergHNeurological symptoms in pharmacotherapy of psychosisActa Psychiatr Scand196440102710.1111/j.1600-0447.1964.tb05731.x14217630
    Back to article
  3. 3
    FahnSJankovicJHallettMThe tardive syndromes: Phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromesFahnSJankovicJHallettMPrinciples and practice of movement disorders, 2nd ed.Philadelphia, PAElsevier Sanders2011p 415446
    Back to article
  4. 4
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., Text Revision (DSM-IV-TR)Washington, DCAmerican Psychiatric Association2000p 803805
    Back to article
  5. 5
    PolizosPEngelhardtDMHoffmanSPWaizerJNeurological consequences of psychotropic drug withdrawal in schizophrenic childrenJ Autism Child Schizophr1973324725310.1007/BF015382824800390
    Back to article
  6. 6
    PeñaMSYalthoTCJankovicJTardive dyskinesia and other movement disorders secondary to aripiprazoleMov Disord20112614715210.1002/mds.2340220818603
    Back to article
  7. 7
    AlbayrakYEkinciODuloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case reportJ Clin Psychopharmacol20123272372410.1097/JCP.0b013e318268661922926615
    Back to article
  8. 8
    BirthiPWaltersCKarandikarNA rare case of tardive dyskinesia and akathisia induced by citalopramPM R2010297397520970768
    Back to article
  9. 9
    ChakrabartiSChandPKLithium-induced tardive dystoniaNeurol India20025047347512577099
    Back to article
  10. 10
    FabianiGPastroPCFroehnerCParkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizineArq Neuropsiquiatr20046278478810.1590/S0004-282X200400050000815476069
    Back to article
  11. 11
    SeemanPDopamine D2 receptors as treatment targets in schizophreniaClin Schizophr Relat Psychoses20104567310.3371/CSRP.4.1.520643630
    Back to article
  12. 12
    SegmanRHHeresco-LevyUFinkelBet alAssociation between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophreniaMol Psychiatry2001622522910.1038/sj.mp.400084211317227
    Back to article
  13. 13
    GlazerWMExpected incidence of tardive dyskinesia associated with atypical antipsychoticsJ Clin Psychiatry200061212610739327
    Back to article
  14. 14
    TeoJTEdwardsMJBhatiaKTardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesisMov Disord2012271205121510.1002/mds.2510722865512
    Back to article
  15. 15
    GittisAHLeventhalDKFensterheimBAPettiboneJRBerkeJDKreitzerACSelective inhibition of striatal fast-spiking interneurons causes dyskinesiaJ Neurosci201131157271573110.1523/JNEUROSCI.3875-11.201122049415
    Back to article
  16. 16
    MargoleseHCChouinardGKolivakisTTBeauclairLMillerRAnnableLTardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of inductionCan J Psychiatry20055054154716262110
    Back to article
  17. 17
    GunneLHäggströmJSjöquistBAssociation with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesisNature198430934734910.1038/309347a06727989
    Back to article
  18. 18
    ElkashefAMWyattRJTardive dyskinesia: possible involvement of free radicals and treatment with vitamin ESchizophr Bull19992573174010.1093/oxfordjournals.schbul.a03341410667743
    Back to article
  19. 19
    KiriakakisVBhatiaKPGuinnNPMarsdenCDThe natural history of tardive dystonia. A long-term follow-up study of 107 casesBrain19981212053206610.1093/brain/121.11.20539827766
    Back to article
  20. 20
    ChoCHLeeHJOxidative stress and tardive dyskinesia: Pharmacogenetic evidenceProg Neuropsychopharmacol Biol Psychiatry2012pii: S0278–5846(12)00274-6. doi:10.1016/j.pnpbp.2012.10.018
    Back to article
  21. 21
    CadetJLPerumalASChronic treatment with prolixin causes oxidative stress in rat brainBiol Psychiatry19902873874010.1016/0006-3223(90)90461-A2242392
    Back to article
  22. 22
    LohrJBKuczenskiRNiculescuABOxidative mechanisms and tardive dyskinesiaCNS Drugs200317476210.2165/00023210-200317010-0000412467492
    Back to article
  23. 23
    ZhangZJZhangXBHouGYaoHReynoldsGPInteraction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesiaPsychiatr Genet20031318719210.1097/00041444-200309000-0001012960753
    Back to article
  24. 24
    KulkarniSKNaiduPSPathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectivesDrugs Today200339194910.1358/dot.2003.39.1.79943012669107
    Back to article
  25. 25
    LererBSegmanRHFangerauHet alPharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphismNeuropsychopharmacology20022710511910.1016/S0893-133X(02)00293-212062911
    Back to article
  26. 26
    ChenCHWeiFCKoongFJHsiaoKJAssociation of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophreniaBiol Psychiatry19974182782910.1016/S0006-3223(96)00543-49084902
    Back to article
  27. 27
    TanECChongSAMahendranRDongFTanCHSusceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptorBiol Psychiatry20015014414710.1016/S0006-3223(01)01076-911526996
    Back to article
  28. 28
    BakkerPRvan HartenPNvan OsJAntipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactionsMol Psychiatry20081354455610.1038/sj.mp.400214218180754
    Back to article
  29. 29
    AndreassenOAMacEwanTGulbrandsenAKMcCreadieRGSteenVMNon-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patientsPsychopharmacology (Berl)199713117417910.1007/s0021300502819201806
    Back to article
  30. 30
    KaneJMSmithJMTardive dyskinesia: prevalence and risk factors, 1959 to 1979Arch Gen Psychiatry19823947348110.1001/archpsyc.1982.042900400690106121548
    Back to article
  31. 31
    RaoASCamilleriMReview article: metoclopramide and tardive dyskinesiaAliment Pharmacol Ther201031111910.1111/j.1365-2036.2009.04189.x19886950
    Back to article
  32. 32
    CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: systematic review of one-year studiesAm J Psychiatry200416141442514992963
    Back to article
  33. 33
    TurronePSeemanMVSilvestriSEstrogen receptor activation and tardive dyskinesiaCan J Psychiatry20004528829010779888
    Back to article
  34. 34
    WonodiIAdamiHMCassadySLSherrJDAvilaMTThakerGKEthnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research centerJ Clin Psychopharmacol20042459259810.1097/01.jcp.0000144888.43449.5415538119
    Back to article
  35. 35
    TarsyDBaldessariniRJEpidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?Mov Disord20062158959810.1002/mds.2082316532448
    Back to article
  36. 36
    BhidayasiriRBoonyawairojSSpectrum of tardive syndromes: clinical recognition and managementPostgrad Med J20118713214110.1136/pgmj.2010.10323421131613
    Back to article
  37. 37
    Orti-ParejaMJimenez-JimenezFJVasquezAet alDrug-induced tardive syndromesParkinsonism Relat Disord19995596510.1016/S1353-8020(99)00015-218591121
    Back to article
  38. 38
    KaneJMWoernerMBorensteinMWegnerJLiebermanJIntegrating incidence and prevalence of tardive dyskinesiaPsychopharmacol Bull1986222542582873613
    Back to article
  39. 39
    KangUJBurkeREFahnSNatural history and treatment of tardive dystoniaMov Disord1986119320810.1002/mds.8700103052904118
    Back to article
  40. 40
    MorgensternHGlazerWMIdentifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale tardive dyskinesia studyArch Gen Psychiatry19935072373310.1001/archpsyc.1993.018202100570078102845
    Back to article
  41. 41
    MejiaNIJankovicJTardive dyskinesia and withdrawal emergent syndrome in childrenExpert Rev Neurother20101089390110.1586/ern.10.5820518606
    Back to article
  42. 42
    LimTTAhmedAItinIGostkowskiMRudolphJCooperSFernandezHHIs 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease?Int J Neurosci201312317017423078283
    Back to article
  43. 43
    TrollorJNChenXChittyKSachdevPSComparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychoticsBr J Psychiatry2012201525622626633
    Back to article
  44. 44
    JankovicJTardive syndromes and other drug-induced movement disordersClin Neuropharmacol19951819721410.1097/00002826-199506000-000018635179
    Back to article
  45. 45
    StacyMCardosoFJankovicJTardive stereotypy and other movement disorders in tardive dyskinesiasNeurology19934393794110.1212/WNL.43.5.9378492949
    Back to article
  46. 46
    MehannaRJankovicJRespiratory disorders associated with dystoniaMov Disord2012271816181910.1002/mds.2526923208724
    Back to article
  47. 47
    YassaRLalSRespiratory irregularity and tardive dyskinesia. A prevalence studyActa Psychiatr Scand19867350651010.1111/j.1600-0447.1986.tb02717.x2875609
    Back to article
  48. 48
    BurkeREKangUJJankovicJMillerLGFahnSTardive akathisia: an analysis of clinical features and response to open therapeutic trialsMov Disord1989415717510.1002/mds.8700402082567492
    Back to article
  49. 49
    FountoulakisKNSamaraMSiaperaMIacovidesATardive Tourette-like syndrome: a systematic reviewInt Clin Psychopharmacol20112623724210.1097/YIC.0b013e32834aa92421811171
    Back to article
  50. 50
    StacyMJankovicJTardive tremorMov Disord19927535710.1002/mds.8700701101348352
    Back to article
  51. 51
    TominagaHFukuzakoHIzumiKet alTardive myoclonusLancet1987132210.1016/S0140-6736(87)92042-32880125
    Back to article
  52. 52
    LorberboymMTrevesTAMelamedELamplYHellmannMDjaldettiR[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s diseaseMov Disord20062151051410.1002/mds.2074816250023
    Back to article
  53. 53
    BowerJHDicksonDWTaylorLMaraganoreDMRoccaWAClinical correlates of the pathology underlying parkinsonism: a population perspectiveMov Disord20021791091610.1002/mds.1020212360539
    Back to article
  54. 54
    Foubert-SamierAHelmerCPerezFet alPast exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohortNeurology2012791615162110.1212/WNL.0b013e31826e25ce23019267
    Back to article
  55. 55
    KuoSHJankovicJTardive GaitClin Neurol Neurosurg200811019820110.1016/j.clineuro.2007.09.01317997030
    Back to article
  56. 56
    LanganJMartinDShajahanPSmithDJAntipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series reportBMC Psychiatry20121221410.1186/1471-244X-12-21423194104
    Back to article
  57. 57
    FordBGreenePFahnSOral and genital tardive pain syndromesNeurology1994442115211910.1212/WNL.44.11.21157969969
    Back to article
  58. 58
    SchneiderSADusekPHardyJWestenbergerAJankovicJBhatiaKPGenetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA)Current Neuropharmacol2013115979
    Back to article
  59. 59
    Baizabal-CarvalloJFBonnetCJankovicJMovement disorders in systemic lupus erythematosus and the antiphospholipid syndromeJ Neurol Transm2013(in press). [Epub ahead of print.]
    Back to article
  60. 60
    Baizabal-CarvalloJFStoccoAMuscalEJankovicJThe spectrum of movement disorders in children with anti-NMDA receptor encephalitisMov Disord20132854354710.1002/mds.2535423400857
    Back to article
  61. 61
    Baizabal-CarvalloJFJankovicJMovement disorders in autoimmune diseasesMov Disord20122793594610.1002/mds.2501122555904
    Back to article
  62. 62
    BlanchetPJPopoviciRGuitardFRompréPHLamarcheCLavigneGJPain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjectsMov Disord2008231837184210.1002/mds.2210218759358
    Back to article
  63. 63
    MorganJCSethiKDDrug-induced tremorLancet Neurol2005486687610.1016/S1474-4422(05)70250-716297844
    Back to article
  64. 64
    EmsleyRTurnerHJSchronenJet alA single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesiaJ Clin Psychiatry20046569670110.4088/JCP.v65n051615163258
    Back to article
  65. 65
    JankovicJClarence-SmithKTetrabenazine for the treatment of chorea and other hyperkinetic movement disordersExpert Review of Neurotherapeutics2011111509152310.1586/ern.11.14922014129
    Back to article
  66. 66
    Jimenez-ShahedJJankovicJTetrabenazine for treatment of chorea associated with Huntington’s diseaseExpert Opinion on Orphan Drugs2013142343610.1517/21678707.2013.787358
    Back to article
  67. 67
    KenneyCJankovicJTetrabenazine in the treatment of hyperkinetic movement disordersExpert Rev Neurother2006671710.1586/14737175.6.1.716466307
    Back to article
  68. 68
    FahnSA therapeutic approach to tardive dyskinesiaJ Clin Psychiatry19854619242858474
    Back to article
  69. 69
    AngusSSugarsJBoltezarRKoskewichSSchneiderNMA controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesiaJ Clin Psychopharmacol199717889110.1097/00004714-199704000-0000410950469
    Back to article
  70. 70
    SoaresKVMcGrathJJDeeksJJGamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesiaCochrane Database Syst Rev2001(2)CD00020311405955
    Back to article
  71. 71
    ThakerGKNguyenJAStraussMEJacobsonRKaupBATammingaCAClonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategyAm J Psychiatry19901474454511969244
    Back to article
  72. 72
    StewartRMRollinsJBeckhamBet alBaclofen in tardive dyskinesia patients maintained on neurolepticsClin Neuropharmacol1982536537310.1097/00002826-198212000-000046130838
    Back to article
  73. 73
    AlabedSLatifehYMohammadHARifaiAGamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesiaCochrane Database Syst Rev2011(4)CD00020321491376
    Back to article
  74. 74
    BergmanJDwolatzkyTBrettholzILernerVBeneficial effect of donepezil in the treatment of elderly patients with tardive movement disordersJ Clin Psychiatry20056610711010.4088/JCP.v66n011515669896
    Back to article
  75. 75
    Van HartenPNHoekHWMatroosGEvan OsJEvidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VIEur Neuropsychopharmacol20081815215510.1016/j.euroneuro.2007.07.00417822885
    Back to article
  76. 76
    McGrathJSoares-WeiserKVitamin E for neuroleptic-induced tardive dyskinesiaCochrane Database Syst Rev2001(4)CD00020911687073
    Back to article
  77. 77
    ZhangXYZhouDFCaoLYXuCQChenDCWuGYThe effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trialJ Clin Psychopharmacol200424838610.1097/01.jcp.0000104912.75206.2b14709952
    Back to article
  78. 78
    IwataYIrieSUchidaHSuzukiTWatanabeKIwashitaSMimuraMEffects of zonisamide on tardive dyskinesia: a preliminary open-label trialJ Neurol Sci201231513714010.1016/j.jns.2011.12.01022285275
    Back to article
  79. 79
    LernerVMiodownikCKaptsanAet alVitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover studyAm J Psychiatry20011581511151411532741
    Back to article
  80. 80
    ShamirEBarakYShalmanIet alMelatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover studyArch Gen Psychiatry2001581049105210.1001/archpsyc.58.11.104911695951
    Back to article
  81. 81
    WalnOJankovic J. Zolpidem improves tardive dyskinesia and akathisiaMov Disord2013doi:10.1002/mds.25480. [Epub ahead of print]
    Back to article
  82. 82
    JankovicJBotulinum toxinKompolitiKVerhagen MetmanLEncyclopedia of movement disorders, 1st ed.Oxford: Academic Press2010p 144150
    Back to article
  83. 83
    Ramirez-CastanedaJJankovicJLong-term efficacy, safety, and side effect profile of botulinum toxin injections in dystoniaToxins2013524926610.3390/toxins502024923381141
    Back to article
  84. 84
    SpindlerMAGalifianakisNBWilkinsonJRDudaJEGlobus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literatureParkinsonism Relat Disord20131914114710.1016/j.parkreldis.2012.09.01623099106
    Back to article
  85. 85
    WysokińskiAIntensive electroconvulsive therapy in drug resistant neuroleptic malignant syndrome – case reportPsychiatr Danub20122421922222706423
    Back to article
  86. 86
    AiaPGRevueltaGJCloudLJFactorSATardive dyskinesiaCurr Treat Options Neurol20111323124110.1007/s11940-011-0117-x21365202
    Back to article
  87. 87
    FernandezHHFriedmanJHClassification and treatment of tardive syndromesNeurologist20039162710.1097/01.nrl.0000038585.58012.9712801428
    Back to article
DOI: https://doi.org/10.5334/tohm.165 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Feb 24, 2013
Accepted on: May 30, 2013
Published on: Jul 12, 2013
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Tardive syndrome,
tardive dyskinesia,
dystonia,
akathisia,
dopamine receptor-blocking agents,
neuroleptics

© 2013 Olga Waln, Joseph Jankovic, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 3 (2013): Issue 0Next article